The case control study of Option B+ (Tenofovir/Lamivudine/Efavirenz (TLE) combined) as one of the strategies to eliminate mother to child HIV transmission (eMTCT)

Trial Profile

The case control study of Option B+ (Tenofovir/Lamivudine/Efavirenz (TLE) combined) as one of the strategies to eliminate mother to child HIV transmission (eMTCT)

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Efavirenz/lamivudine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2018 New trial record
    • 04 Mar 2018 Results of vertical transmission among pregnant/breastfeeding women on TLE were presented at the 18th International Congress on Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top